ScreenerHero

ANABAnaptysBio, Inc.

NAS · US · Healthcare · Biotechnology · anaptysbio.com
57.74USD-2.56%Mkt Cap: 1.71B $P/E: —

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selectiv…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.71B $
Enterprise Value1.64B $
Revenue (TTM)232.39M $
Gross Profit103.61M $
Net Income (TTM)-13.23M $
Revenue/Share8.220 USD
Last Price57.74 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0327241065
Valuation
P/E (Trailing)—
P/E (Forward)10.83
PEG—
EV/EBITDA39.69
EV/Revenue7.06
P/S7.22
P/B129.13
EPS (TTM)-0.97
EPS (Forward)5.24
52W Range
11.4076% of range72.36
52W High72.36 USD
52W Low11.40 USD
Profitability
Gross Margin44.58%
Oper. Margin-135.53%
EBITDA Margin17.79%
Profit Margin-5.64%
ROE-35.56%
ROA-3.63%
Growth
Revenue Growth-8.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF19.70M $
CapEx (TTM)87.00K $
FCF Margin3.58%
FCF Yield0.49%
Net Debt-9.10M $
Net Debt/EBITDA-0.22
Balance Sheet
Debt/Equity0.38
Current Ratio7.58
Quick Ratio7.49
Book Value/Sh0.4390 USD
Cash/Share9.844 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split15:10
Split DateApr 20, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)87.09 USD
Upside (mean)+50.8%
Target Range70.00 USD – 140.00 USD
$70.00+50.8% to mean$140.00
# Analysts11
Ownership
Shares Out.29.61M
Float19.79M
Insiders5.68%
Institutions106.04%
Short Interest
Short Ratio6.7d
Short % Float40.60%
Short % Out.18.24%
Shares Short5.40M
Short (prev mo.)5.15M
Technical
SMA 5058.23 (-0.8%)
SMA 20044.59 (+29.5%)
Beta0.40
S&P 52W Chg18.16%
Avg Vol (30d)556.88K
Avg Vol (10d)348.59K
Technical Indicators
RSI (14)51.8
MACD0.2682
MACD Signal-0.3304
MACD Hist.+0.5986
BB Upper60.01 USD
BB Middle55.60 USD
BB Lower51.19 USD
BB Width15.86%
ATR (14)2.975 USD
Vol Ratio (20d)0.69x